ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...

Abbott, a global healthcare leader, announced that the US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a ...

Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also ...

Abbott has recalled a small number of Freestyle Libre 3 sensors distributed in the U.S. in the first half of May, the company said Wednesday. Internal testing found a subset of three lots of the ...

Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's issuing a voluntary medical device correction for some of its FreeStyle ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Abbott issued a medical device correction for some ...

- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people ...